Continuous combined hormonal replacement therapy and the risk of endometrial cancer-preliminary report

Menopause

Volumn 1, Issue 1, 1994, Pages 57-60

  Goodman, Lois ^a   Awwad, Johnny ^b   Marc, Kathleen ^a   Schiff, Isaac ^b  

^a NEWTON WELLESLEY HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endometrial cancer; Estrogen; Hormone replacement therapy

Indexed keywords

EID: 0001810953     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/00042192-199400110-00009     Document Type: Article

References (20)

1. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischemic heart disease. Lancet 1981;i;858.
2. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273.
3. Staland B. Continuous treatment with natural oestrogens and progestagens. A method to avoid endometrial stimulation. Maturitas 1981;3:145.
4. Magos A, Brincat M, Studd JWW, Wardle P, Schleringer P, O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogens and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496.
5. Leather AT, Savvas M, Studd JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991;78:1008.
6. Zeil H, Finkle W. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167.
7. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262.
8. Cramer DW, Knapp RC. Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol 1979;54:521.
9. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;313:969.
10. Clark J, Pasko A, Peck F. Nuclear binding and retention of the receptor and estrogen complex: relation to the agonistic and antagonistic properties of estrol. Endocrinology 1977;100:91.
11. Gurpide E. Hormones and gynecologic cancer. Cancer 1976;38:503.
12. Jikihara H, Terada N, Yamamoto R, et al. Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol 1992;167:207.
13. Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95.
14. Sporrong T, Hellgren M, Samsioe G, Mattsson LA. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988;95:1042.
15. Mortel R, Zaino RJ, Satyaswaroop GP. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. Am J Obstet Gynecol 1990;162:928.
16. Hirvonen R, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560.
17. Nisker JA, Woods BT. Female hormones and the postmenopausal endometrium. N Engl J Med 1982;306:1424.
18. Stockdale AD, Rostom AY. Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations. Clin Pharmacokinet 1989;16:129.
19. Cornette JC, Kirton KT, Duncan GW. Measurement of medroxyprogesterone acetate by radioimmunoassay. J Clin Endocrinol Metab 1971;33:459.
20. Etienne MC, Milano G, Frenay M, Renee N, Francois E, Thyss A, Schneider M, Namer M. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J Clin Oncol 1992;210:1176.